F-star Therapeutics, Inc.
NASDAQ: FSTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Eliot Richard Forster
- Employees
- 84
- Headquarters
- Cambridge, United Kingdom
- IPO year
- 2021
- Market cap
- $156.5M
- Website
- https://www.f-star.com
Loading FSTX…
Loading profile data…Frequently asked questions about FSTX
What does F-star Therapeutics, Inc. (FSTX) do?
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to inventing tetravalent bispecific antibodies for the treatment of cancer, particularly within the field of immuno-oncology. The company's primary investigational product, FS118, is currently in a Phase 2 proof-of-concept trial, evaluating its efficacy in head and ne...
Where does FSTX trade?
F-star Therapeutics, Inc. (FSTX) trades on the NASDAQ Capital Market.
What sector is FSTX in?
F-star Therapeutics, Inc. (FSTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of F-star Therapeutics, Inc.?
Eliot Richard Forster is the chief executive officer of F-star Therapeutics, Inc. (FSTX).
Where is F-star Therapeutics, Inc. headquartered?
F-star Therapeutics, Inc. is headquartered in United Kingdom.
Does FSTX pay a dividend?
F-star Therapeutics, Inc. (FSTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did FSTX go public?
F-star Therapeutics, Inc. (FSTX) completed its initial public offering in 2021.